Molbio Diagnostics Limited
ListedMolecular Diagnostics · Mainboard IPO · INE869T01028
Price band
₹768 – ₹807
Lot size
18 shares
Min. investment
₹14,526
Issue size
₹940 Cr
Face value
₹1
Registrar
Kfin Technologies Ltd.
Issue timeline
Bidding opens
10 Aug 2026
Bidding closes
12 Aug 2026
Allotment
13 Aug 2026
Listing
17 Aug 2026
Final subscription
18,83,421
applications
₹28,356 Cr
bid value
| Category | Bid for | ₹ Cr* |
|---|---|---|
| Qualified Institutional (QIB) | 25,25,74,650 | 20,383 |
| Non-Institutional >₹10L (bNII) | 4,24,51,614 | 3,426 |
| Non-Institutional ₹2–10L (sNII) | 1,91,90,376 | 1,549 |
| Retail (RII) | 3,69,38,736 | 2,981 |
| Employees | 2,20,878 | 18 |
| Total | 35,13,76,254 | 28,356 |
Live category-wise demand from NSE only. Add each category's offered shares (from the RHP) in IPO Master to show the subscription (x) multiple.
About the company
Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases.
Issue details
Issue size
₹940 Cr
Fresh issue
₹200 Cr
Offer for sale
₹740 Cr
Industry
Molecular Diagnostics
Promoter holding (pre)
46.65%
Promoter holding (post)
53.35
Financials (₹ Cr)
| Metric | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Total income | 840.66 | 1,027.94 | 1455.17 Cr |
| EBITDA | 185.09 | 256.64 | 328.24 |
| Profit after tax | 83.54 | 138.58 | 164.14 Cr |
| Net worth | 807.94 | 952.95 | 1144.68 Cr |
| Total assets | 1,221.06 | 1,461.56 | 2,148.42 |
| Total borrowing | 174.58 | 123.16 | 412.64 |
Objects of the issue
- Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit.
Strengths
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Risks
- Dependence on a limited number of products for revenue generation.
- Intense competition in the molecular diagnostics market.
- Regulatory challenges in different countries.
- Potential for product liability claims.
Documents
Calculate your bid
At cut-off price ₹807
Lots
1
- Shares
- 18
- Amount
- ₹14,526
UPI mandate — funds are blocked, not debited.
- SEBI-registered broker — NSE member 90113
- Funds stay blocked in your own bank — debited only on allotment
- Apply for your whole family from one login